Selected research
Industry Research
Platinum-based Anticancer Drugs Industry Research Report 2026
Market perspective
The global Platinum-based Anticancer Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Platinum-based Anticancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Platinum-based Anticancer Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Platinum-based Anticancer Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Platinum-based Anticancer Drugs include Teva, Sun Pharmaceutical, Qilu Pharmaceutical, Nanjing Pharmaceutical Factory, Mylan, Luoxin, Jiangsu Aosaikang Pharmaceutical, Jiangsu Hengrui Medicine and Fresenius Kabi, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Platinum-based Anticancer Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (Tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Platinum-based Anticancer Drugs Market by Company
Teva
Sun Pharmaceutical
Qilu Pharmaceutical
Nanjing Pharmaceutical Factory
Mylan
Luoxin
Jiangsu Aosaikang Pharmaceutical
Jiangsu Hengrui Medicine
Fresenius Kabi
Yakult honsha
Taj Pharmaceuticals
Sanofi-Aventis
Lingnan Pharmacy
Hospira(Pfizer)
Hisun Pharmaceutical
Hansoh Pharma
Dr Reddy's laboratories
Platinum-based Anticancer Drugs Segment by Type
Oxaliplatin
Carboplatin
Nedaplatin
Cisplatin
Others
Platinum-based Anticancer Drugs Segment by Application
Esophageal Cancer
Breast Cancer
Osteosarcoma
Testicular Cancer
NSCLC
Other
Platinum-based Anticancer Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Platinum-based Anticancer Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Platinum-based Anticancer Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Platinum-based Anticancer Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Platinum-based Anticancer Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Platinum-based Anticancer Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Platinum-based Anticancer Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Oxaliplatin
- Carboplatin
- Nedaplatin
- Cisplatin
- Others
Applications
- Esophageal Cancer
- Breast Cancer
- Osteosarcoma
- Testicular Cancer
- NSCLC
- Other
Companies covered
- Teva
- Sun Pharmaceutical
- Qilu Pharmaceutical
- Nanjing Pharmaceutical Factory
- Mylan
- Luoxin
- Jiangsu Aosaikang Pharmaceutical
- Jiangsu Hengrui Medicine
- Fresenius Kabi
- Yakult honsha
- Taj Pharmaceuticals
- Sanofi-Aventis
- Lingnan Pharmacy
- Hospira(Pfizer)
- Hisun Pharmaceutical
- Hansoh Pharma
- Dr Reddy's laboratories
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Platinum-based Anticancer Drugs Market Size (2021-2032)
- 2.2.2 Global Platinum-based Anticancer Drugs Sales (2021-2032)
- 2.2.3 Global Platinum-based Anticancer Drugs Market Average Price (2021-2032)
- 2.3 Platinum-based Anticancer Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Oxaliplatin
- 2.3.3 Carboplatin
- 2.3.4 Nedaplatin
- 2.3.5 Cisplatin
- 2.3.6 Others
- 2.4 Platinum-based Anticancer Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Esophageal Cancer
- 2.4.3 Breast Cancer
- 2.4.4 Osteosarcoma
- 2.4.5 Testicular Cancer
- 2.4.6 NSCLC
- 2.4.7 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Platinum-based Anticancer Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Platinum-based Anticancer Drugs Sales (Tons) of Manufacturers (2021-2026)
- 3.3 Global Platinum-based Anticancer Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Platinum-based Anticancer Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Platinum-based Anticancer Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Platinum-based Anticancer Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Platinum-based Anticancer Drugs, Product Type & Application
- 3.8 Global Manufacturers of Platinum-based Anticancer Drugs, Established Date
- 3.9 Global Platinum-based Anticancer Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Teva
- 4.1.1 Teva Company Information
- 4.1.2 Teva Business Overview
- 4.1.3 Teva Platinum-based Anticancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Teva Platinum-based Anticancer Drugs Product Portfolio
- 4.1.5 Teva Recent Developments
- 4.2 Sun Pharmaceutical
- 4.2.1 Sun Pharmaceutical Company Information
- 4.2.2 Sun Pharmaceutical Business Overview
- 4.2.3 Sun Pharmaceutical Platinum-based Anticancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Sun Pharmaceutical Platinum-based Anticancer Drugs Product Portfolio
- 4.2.5 Sun Pharmaceutical Recent Developments
- 4.3 Qilu Pharmaceutical
- 4.3.1 Qilu Pharmaceutical Company Information
- 4.3.2 Qilu Pharmaceutical Business Overview
- 4.3.3 Qilu Pharmaceutical Platinum-based Anticancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Qilu Pharmaceutical Platinum-based Anticancer Drugs Product Portfolio
- 4.3.5 Qilu Pharmaceutical Recent Developments
- 4.4 Nanjing Pharmaceutical Factory
- 4.4.1 Nanjing Pharmaceutical Factory Company Information
- 4.4.2 Nanjing Pharmaceutical Factory Business Overview
- 4.4.3 Nanjing Pharmaceutical Factory Platinum-based Anticancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Nanjing Pharmaceutical Factory Platinum-based Anticancer Drugs Product Portfolio
- 4.4.5 Nanjing Pharmaceutical Factory Recent Developments
- 4.5 Mylan
- 4.5.1 Mylan Company Information
- 4.5.2 Mylan Business Overview
- 4.5.3 Mylan Platinum-based Anticancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Mylan Platinum-based Anticancer Drugs Product Portfolio
- 4.5.5 Mylan Recent Developments
- 4.6 Luoxin
- 4.6.1 Luoxin Company Information
- 4.6.2 Luoxin Business Overview
- 4.6.3 Luoxin Platinum-based Anticancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Luoxin Platinum-based Anticancer Drugs Product Portfolio
- 4.6.5 Luoxin Recent Developments
- 4.7 Jiangsu Aosaikang Pharmaceutical
- 4.7.1 Jiangsu Aosaikang Pharmaceutical Company Information
- 4.7.2 Jiangsu Aosaikang Pharmaceutical Business Overview
- 4.7.3 Jiangsu Aosaikang Pharmaceutical Platinum-based Anticancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Jiangsu Aosaikang Pharmaceutical Platinum-based Anticancer Drugs Product Portfolio
- 4.7.5 Jiangsu Aosaikang Pharmaceutical Recent Developments
- 4.8 Jiangsu Hengrui Medicine
- 4.8.1 Jiangsu Hengrui Medicine Company Information
- 4.8.2 Jiangsu Hengrui Medicine Business Overview
- 4.8.3 Jiangsu Hengrui Medicine Platinum-based Anticancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Jiangsu Hengrui Medicine Platinum-based Anticancer Drugs Product Portfolio
- 4.8.5 Jiangsu Hengrui Medicine Recent Developments
- 4.9 Fresenius Kabi
- 4.9.1 Fresenius Kabi Company Information
- 4.9.2 Fresenius Kabi Business Overview
- 4.9.3 Fresenius Kabi Platinum-based Anticancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Fresenius Kabi Platinum-based Anticancer Drugs Product Portfolio
- 4.9.5 Fresenius Kabi Recent Developments
- 4.10 Yakult honsha
- 4.10.1 Yakult honsha Company Information
- 4.10.2 Yakult honsha Business Overview
- 4.10.3 Yakult honsha Platinum-based Anticancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Yakult honsha Platinum-based Anticancer Drugs Product Portfolio
- 4.10.5 Yakult honsha Recent Developments
- 4.11 Taj Pharmaceuticals
- 4.11.1 Taj Pharmaceuticals Company Information
- 4.11.2 Taj Pharmaceuticals Business Overview
- 4.11.3 Taj Pharmaceuticals Platinum-based Anticancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Taj Pharmaceuticals Platinum-based Anticancer Drugs Product Portfolio
- 4.11.5 Taj Pharmaceuticals Recent Developments
- 4.12 Sanofi-Aventis
- 4.12.1 Sanofi-Aventis Company Information
- 4.12.2 Sanofi-Aventis Business Overview
- 4.12.3 Sanofi-Aventis Platinum-based Anticancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Sanofi-Aventis Platinum-based Anticancer Drugs Product Portfolio
- 4.12.5 Sanofi-Aventis Recent Developments
- 4.13 Lingnan Pharmacy
- 4.13.1 Lingnan Pharmacy Company Information
- 4.13.2 Lingnan Pharmacy Business Overview
- 4.13.3 Lingnan Pharmacy Platinum-based Anticancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Lingnan Pharmacy Platinum-based Anticancer Drugs Product Portfolio
- 4.13.5 Lingnan Pharmacy Recent Developments
- 4.14 Hospira(Pfizer)
- 4.14.1 Hospira(Pfizer) Company Information
- 4.14.2 Hospira(Pfizer) Business Overview
- 4.14.3 Hospira(Pfizer) Platinum-based Anticancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Hospira(Pfizer) Platinum-based Anticancer Drugs Product Portfolio
- 4.14.5 Hospira(Pfizer) Recent Developments
- 4.15 Hisun Pharmaceutical
- 4.15.1 Hisun Pharmaceutical Company Information
- 4.15.2 Hisun Pharmaceutical Business Overview
- 4.15.3 Hisun Pharmaceutical Platinum-based Anticancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Hisun Pharmaceutical Platinum-based Anticancer Drugs Product Portfolio
- 4.15.5 Hisun Pharmaceutical Recent Developments
- 4.16 Hansoh Pharma
- 4.16.1 Hansoh Pharma Company Information
- 4.16.2 Hansoh Pharma Business Overview
- 4.16.3 Hansoh Pharma Platinum-based Anticancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 Hansoh Pharma Platinum-based Anticancer Drugs Product Portfolio
- 4.16.5 Hansoh Pharma Recent Developments
- 4.17 Dr Reddy's laboratories
- 4.17.1 Dr Reddy's laboratories Company Information
- 4.17.2 Dr Reddy's laboratories Business Overview
- 4.17.3 Dr Reddy's laboratories Platinum-based Anticancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.17.4 Dr Reddy's laboratories Platinum-based Anticancer Drugs Product Portfolio
- 4.17.5 Dr Reddy's laboratories Recent Developments
5 Global Platinum-based Anticancer Drugs Market Scenario by Region
- 5.1 Global Platinum-based Anticancer Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Platinum-based Anticancer Drugs Sales by Region: 2021-2032
- 5.2.1 Global Platinum-based Anticancer Drugs Sales by Region: 2021-2026
- 5.2.2 Global Platinum-based Anticancer Drugs Sales by Region: 2027-2032
- 5.3 Global Platinum-based Anticancer Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Platinum-based Anticancer Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Platinum-based Anticancer Drugs Revenue by Region: 2027-2032
- 5.4 North America Platinum-based Anticancer Drugs Market Facts & Figures by Country
- 5.4.1 North America Platinum-based Anticancer Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Platinum-based Anticancer Drugs Sales by Country (2021-2032)
- 5.4.3 North America Platinum-based Anticancer Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Platinum-based Anticancer Drugs Market Facts & Figures by Country
- 5.5.1 Europe Platinum-based Anticancer Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Platinum-based Anticancer Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Platinum-based Anticancer Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Platinum-based Anticancer Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Platinum-based Anticancer Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Platinum-based Anticancer Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Platinum-based Anticancer Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Platinum-based Anticancer Drugs Market Facts & Figures by Country
- 5.7.1 South America Platinum-based Anticancer Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Platinum-based Anticancer Drugs Sales by Country (2021-2032)
- 5.7.3 South America Platinum-based Anticancer Drugs Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Platinum-based Anticancer Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Platinum-based Anticancer Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Platinum-based Anticancer Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Platinum-based Anticancer Drugs Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Platinum-based Anticancer Drugs Sales by Type (2021-2032)
- 6.1.1 Global Platinum-based Anticancer Drugs Sales by Type (2021-2032) & (Tons)
- 6.1.2 Global Platinum-based Anticancer Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Platinum-based Anticancer Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Platinum-based Anticancer Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Platinum-based Anticancer Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Platinum-based Anticancer Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Platinum-based Anticancer Drugs Sales by Application (2021-2032)
- 7.1.1 Global Platinum-based Anticancer Drugs Sales by Application (2021-2032) & (Tons)
- 7.1.2 Global Platinum-based Anticancer Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Platinum-based Anticancer Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Platinum-based Anticancer Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Platinum-based Anticancer Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Platinum-based Anticancer Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Platinum-based Anticancer Drugs Value Chain Analysis
- 8.1.1 Platinum-based Anticancer Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Platinum-based Anticancer Drugs Production Mode & Process
- 8.2 Platinum-based Anticancer Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Platinum-based Anticancer Drugs Distributors
- 8.2.3 Platinum-based Anticancer Drugs Customers
9 Global Platinum-based Anticancer Drugs Analyzing Market Dynamics
- 9.1 Platinum-based Anticancer Drugs Industry Trends
- 9.2 Platinum-based Anticancer Drugs Industry Drivers
- 9.3 Platinum-based Anticancer Drugs Industry Opportunities and Challenges
- 9.4 Platinum-based Anticancer Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst